{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:52:30Z","timestamp":1777899150859,"version":"3.51.4"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0236543","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T17:38:37Z","timestamp":1601660317000},"page":"e0236543","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4262-8344","authenticated-orcid":true,"given":"Afschin","family":"Gandjour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"key":"pone.0236543.ref001","unstructured":"Gemeinsamer Bundesausschuss. Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII\u2014Beschl\u00fcsse \u00fcber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V\u2013Sofosbuvir. 17. July 2014a."},{"issue":"1","key":"pone.0236543.ref002","doi-asserted-by":"crossref","first-page":"e0169401","DOI":"10.1371\/journal.pone.0169401","article-title":"Cost-effectiveness of treating hepatitis C with sofosbuvir\/ledipasvir in Germany","volume":"12","author":"JT Stahmeyer","year":"2017","journal-title":"PLoS One"},{"key":"pone.0236543.ref003","unstructured":"Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in der Bundesrepublik Deutschland. Ausgaben f\u00fcr Arzneimittel gegen Hepatitis C. https:\/\/www.zi.de\/presse\/grafikdesmonats\/ (accessed on April 23, 2018)."},{"key":"pone.0236543.ref004","article-title":"Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Hepatitis C im Jahr 2017","volume":"29","author":"Robert Koch-Institut","year":"2018","journal-title":"Epidemiologisches Bulletin"},{"issue":"2","key":"pone.0236543.ref005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jval.2016.12.015","article-title":"The probabilistic efficiency frontier: a framework for cost-effectiveness analysis in Germany put into practice for hepatitis C treatment options","volume":"20","author":"AC M\u00fchlbacher","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"pone.0236543.ref006","first-page":"e21","article-title":"The probabilistic efficiency frontier: a value assessment of treatment options in hepatitis C","volume":"81","author":"AC M\u00fchlbacher","year":"2019","journal-title":"Gesundheitswesen"},{"key":"pone.0236543.ref007","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. General methods. Version 5.0. K\u00f6ln: IQWiG; 10.07.2017."},{"issue":"1","key":"pone.0236543.ref008","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12913-020-5055-4","article-title":"A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency","volume":"20","author":"A Gandjour","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"pone.0236543.ref009","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1108\/IJPSM-06-2013-0083","article-title":"Public acceptance of different approaches to determine drug reimbursement prices and whether it is influenced by framing: an empirical evaluation in Germany","volume":"27","author":"A Gandjour","year":"2014a","journal-title":"International Journal of Public Sector Management"},{"issue":"2","key":"pone.0236543.ref010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11586640-000000000-00000","article-title":"Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules","volume":"9","author":"A Gandjour","year":"2011","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"pone.0236543.ref011","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10729-011-9186-3","article-title":"Presenting Germany's drug pricing rule as a cost-per-QALY rule.","volume":"15","author":"A Gandjour","year":"2012","journal-title":"Health Care Manag Sci"},{"issue":"2","key":"pone.0236543.ref012","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"D Husereau","year":"2013","journal-title":"Value Health."},{"key":"pone.0236543.ref013","unstructured":"Janssen Cilag. Telaprevir (INCIVO\u00ae). Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Modul 3A. Behandlung der chronischen Hepatitis-C-Infektion, Genotyp 1 bei erwachsenen Patienten mit kompensierter Lebererkrankung (einschl. Zirrhose). Stand: 14.10.2011."},{"issue":"10","key":"pone.0236543.ref014","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40273-015-0291-x","article-title":"Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic Assessments","volume":"33","author":"IMPROvED Consortium","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"7543","key":"pone.0236543.ref015","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.38737.607558.80","article-title":"Bias in published cost effectiveness studies: systematic review","volume":"332","author":"CM Bell","year":"2006","journal-title":"BMJ"},{"key":"pone.0236543.ref016","article-title":"Tragende Gr\u00fcnde zum Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII\u2014Beschl\u00fcsse \u00fcber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V\u2013Sofosbuvir","volume":"17","author":"Gemeinsamer Bundesausschuss","year":"2014b"},{"key":"pone.0236543.ref017","first-page":"CD012143","article-title":"Direct-acting antivirals for chronic hepatitis C","volume":"6","author":"JC Jakobsen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"pone.0236543.ref018","first-page":"A-362","article-title":"Der Fall Sofosbuvir: Zur Logik von Arzneimittelpreisen","volume":"112","author":"A Gandjour","year":"2015a","journal-title":"Dtsch Arztebl"},{"issue":"9","key":"pone.0236543.ref019","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40273-015-0317-4","article-title":"Comment on: \"Healthy decisions: towards uncertainty tolerance in healthcare policy\"","volume":"33","author":"A Gandjour","year":"2015b","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"pone.0236543.ref020","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/11592580-000000000-00000","article-title":"Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing?","volume":"29","author":"A Gerber","year":"2011","journal-title":"Pharmacoeconomics"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0236543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T17:39:05Z","timestamp":1601660345000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0236543"}},"subtitle":[],"editor":[{"given":"George","family":"Vousden","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0236543","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,2]]}}}